Founded by Dr Igor Fisher and Prof. Nicolas Mermod in 2001 as a spin-off of the University of Lausanne in Switzerland (UNIL), on the basis of a technology which improves expression of recombinant proteins in mammalian cells invented at UNIL’s Biotechnology Institute, Selexis SA has become a scientific pioneer and global leader in mammalian cell line generation. In close collaboration with UNIL, the company has been setting the pace of innovation in protein expression and establishing new benchmarks in bioproduction for more than a decade.
As of June 14, 2017, JSR Corporation decided to acquire Selexis. While Selexis will be integrated within KBI Biopharma’s operations, to create the most robust and fastest “Gene to GMP” platform in the biopharmaceutical industry, the company will continue to operate with over 30 employees in the Geneva area.
To read the complete press release, please click here.
